http://www.ivdshow.cn
±í¹ÛÒÅ´«Ñ§£¨m6A RNA¼×»ù»¯¡¢RNA¼×»ù»¯¡¢DNA¼×»ù»¯¡¢DNAôǼ׻ù¡¢DNA¼×õ£»ù¡¢DNAôÈ»ù£©£¬·Ö×ÓÉúÎïѧ£¬ÃâÒßÉúÎïѧ£¨Ò»¿¹¡¢¶þ¿¹£©£¬Ï¸°ûÉúÎïѧ£¬ÊµÑéÒÇÆ÷ѧ£¨ºËËáÌáÆðÒÇ¡¢³¬Î¢Á¿·Ö¹â¹â¶È¼Æ£©µÈµÈ²úÆ·Óë¼¼Êõ·þÎñ
±±¾©ÊвýÆ½ÇøÖйشåÉúÃü¿ÆÑ§Ô°¶«60Ã×°¬µÂÔ°
ÁªÏµÈË: Peter Chen / ÓÊÏä: 1951545998@qq.com / QQ: 1513545070 / µç»°: 0313-5935521 / ÊÖ»ú: 18911529660
²é¿´: 433  |  »Ø¸´: 20
¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß ADTechnology µÄ 89 ¸ö½ð±Ò £¬»ØÌû¾ÍÁ¢¼´»ñµÃ 1 ¸ö½ð±Ò£¬Ã¿ÈËÓÐ 1 ´Î»ú»á

ADTechnology

¾èÖú¹ó±ö (ÖøÃûдÊÖ)

±í¹ÛÒÅ´«Ñ§×¨Òµ¹©Ó¦ÉÌ

[É̼ҹ©Ó¦] m6A RNA¼×»ù»¯ÎĿ⹹½¨ÊÔ¼ÁºÐ¡¾²âÐò°æ¡¿-£¨A-P-9016£©-ÀûÆ÷ÔÚÊÖ,ʵÑéÎÞÓÇ

±¾É̼ÒûÓвμÓÓŻݻ£¬Ò»ÆðÑûÇëËûÀ´²Î¼Ó°É ÎҵĴú½ðȯ

´ú½ðȯ0Ôª
ÏÞÁ¿ x ÕÅ
Âú x ¿ÉʹÓã»ÓÐЧÆÚ x Ì죻¹ýÆÚ¿ÉÍË

ÄÚÈÝ

EpiNext m6A RNA¼×»ù»¯ÎĿ⹹½¨ÊÔ¼ÁºÐ(²âÐò°æ)                                »õºÅ£ºA-P-9016

EpiNext CUT&RUN RNA m6A-Seq Kit

±³¾°×ÊÁÏ£ºN6-methyladenosine (m6A) is the most common and abundant modification on RNA molecules present in eukaryotes. Recently, DNA m6A is also identified in multicellular eukaryotes including Caenorhabditis elegans and Drosophila melanogaster, and furthermore identified in higher eukaryotes including plants, mouse and human cells. m6A plays crucial roles in regulating DNA replication, DNA damage, RNA splicing, transposition, transcription, and cellular defense. In human cells, the m6A modification is probably catalyzed by a methyltransferase complex METTL3/METTL14 and removed by the ¦Á-ketoglutarate (¦Á-KG)- and Fe2+-dependent dioxygenases such as FTO, ALKBH5 and TET-like enzymes. It was shown that METTL3 and ¦Á-KG /Fe2+-dependent dioxygenases play important roles in many biological processes, ranging from development and metabolism to fertility. The dynamic and reversible chemical m6A modification on DNA /RNA may also serve as a novel epigenetic marker of profound biological significance. Down-regulation of m6A modification was first characterized in human cancer cells and tissues, relative to their normal controls. m6A is found to be the most regulated DNA modification in cancers. In addition to the regulation in cancer cells, relative to the primary cell/tissues which contain quite low DNA m6A (<0.001%), a hundreds-fold increase of m6A modification was found for in vitro cultured human cells (0.03%-0.22%)¡£

²úÆ·ÃèÊö£ºThis kit is designed for measuring total m6A demethylase activity/inhibition. In an assay with this kit, the unique m6A substrate is stably coated on the strip wells. Active m6A demethylases bind to and demethylate m6A contained in the substrate. The un-demethylated m6A in the substrate can be recognized with a high affinity m6A antibody and the immuno-signal is enhanced with enhancer solution. The ratio or amount of un-demethylated m6A, which is inversely proportional to enzyme activity, can then be colorimetrically quantified through an ELISA-like reaction¡£

²úÆ·ÌØµã£º

1¡¤High enrichment: Use RNA cleavage enzyme mix to simultaneously fragment RNA and cleave/remove any RNA sequences at both ends of the target m6A -containing sequences without affecting RNA regions occupied by the antibody. Short RNA fragments are generated only bound with anti- m6A antibody. True target m6A-enriched regions can, therefore, be reliably identified and high-resolution mapping achieved£»

2¡¤Low Input: Unbound RNA cleavage and immunocapture are processed in the same single-tube, which enables the maximal protection of the target m6A-containing regions and the minimized sample loss, allowing the input RNA to be as low as 500 ng£»

3.Minimal Background: Cleavage of unbound RNA sequences in the two ends of the target m6A-containing sequences enables the minimized MeRIP/sequencing background, allowing data analysis with <10 million reads.
4.Fast, streamlined procedure: The procedure from RNA to library cDNA is less than 6 hours with <1 h of hands-on time£»

5.Highly convenient: The kit contains all required components for each step of the CUT&RUN RNA m6A -Seq, which are sufficient for both m6A-containing RNA sequence capture and captured cDNA library preparation, thereby allowing CUT&RUN RNA m6A ¨CSeq to be the most convenient with reliable and consistent results¡£
¸ü¶àÇë²Î¿¼:²úÆ·ÏêÇém6A RNA¼×»ù»¯ÎĿ⹹½¨ÊÔ¼ÁºÐ¡¾²âÐò°æ¡¿-£¨A-P-9016£©-ÀûÆ÷ÔÚÊÖ,ʵÑéÎÞÓÇ
p-9016-03.png

» ±¾Ìû¸½¼þ×ÊÔ´Áбí

  • »¶Ó­¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
    ±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com
  • ¸½¼þ 1 : A-P-9016-EpiNext_m6A¼×»ù»¯ÎĿ⹹½¨ÊÔ¼ÁºÐ(²âÐò°æ).pdf
  • 2020-06-02 18:13:52, 758.46 K

» ²ÂÄãϲ»¶

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
2Â¥2020-06-02 18:14:16
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
3Â¥2020-06-02 18:19:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ADTechnology

¾èÖú¹ó±ö (ÖøÃûдÊÖ)

±í¹ÛÒÅ´«Ñ§×¨Òµ¹©Ó¦ÉÌ

±í¹ÛÒÅ´«Ñ§£¨m6A RNA¼×»ù»¯¡¢RNA¼×»ù»¯¡¢DNA¼×»ù»¯¡¢DNAôǼ׻ù¡¢DNA¼×õ£»ù¡¢DNAôÈ»ù£©£¬·Ö×ÓÉúÎïѧ£¬ÃâÒßÉúÎïѧ£¨Ò»¿¹¡¢¶þ¿¹£©£¬Ï¸°ûÉúÎïѧ£¬ÊµÑéÒÇÆ÷ѧ£¨ºËËáÌáÆðÒÇ¡¢³¬Î¢Á¿·Ö¹â¹â¶È¼Æ£©µÈµÈ²úÆ·Óë¼¼Êõ·þÎñ
±±¾©ÊвýÆ½ÇøÖйشåÉúÃü¿ÆÑ§Ô°¶«60Ã×°¬µÂÔ°
ÁªÏµÈË: Peter Chen / ÓÊÏä: 1951545998@qq.com / QQ: 1513545070 / µç»°: 0313-5935521 / ÊÖ»ú: 18911529660
4Â¥2020-06-02 18:34:39
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
5Â¥2020-06-03 11:25:36
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
6Â¥2020-06-03 11:34:09
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
7Â¥2020-06-03 13:42:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
8Â¥2020-06-03 16:54:00
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
9Â¥2020-06-03 18:28:36
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
10Â¥2020-06-05 09:57:50
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ADTechnology µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑо­Àú +3 ÉúÎ﹤³Ìµ÷¼Á 2026-03-17 7/350 2026-03-18 20:41 by Wangjingyue
[¿¼ÑÐ] 26µ÷¼Á/²ÄÁÏ/Ó¢Ò»Êý¶þ/×Ü·Ö289/ÒѹýAÇøÏß +7 ²½´¨¿á×Ï123 2026-03-13 7/350 2026-03-18 17:12 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] 286Çóµ÷¼Á +6 lemonzzn 2026-03-16 9/450 2026-03-18 15:31 by vgtyfty
[¿¼ÑÐ] 070300»¯Ñ§319Çóµ÷¼Á +6 ½õÀð0909 2026-03-17 6/300 2026-03-18 13:22 by Iveryant
[¿¼ÑÐ] 265Çóµ÷¼Á +3 ÁºÁºÐ£Ð£ 2026-03-17 3/150 2026-03-18 09:12 by zhukairuo
[¿¼ÑÐ] ¿¼ÑÐÇóµ÷¼Á +3 éÙËÌ. 2026-03-17 4/200 2026-03-17 21:43 by ÓÐÖ»ÀêÅ«
[¿¼ÑÐ] ¿¼Ñл¯Ñ§Ñ§Ë¶µ÷¼Á£¬Ò»Ö¾Ô¸985 +4 ÕÅvvvv 2026-03-15 6/300 2026-03-17 17:15 by ruiyingmiao
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +5 Ð÷ÐÒÓë×Ó 2026-03-17 5/250 2026-03-17 16:40 by laoshidan
[¿¼ÑÐ] 11408 Ò»Ö¾Ô¸Î÷µç£¬277·ÖÇóµ÷¼Á +3 zhouzhen654 2026-03-16 3/150 2026-03-17 07:03 by laoshidan
[¿¼ÑÐ] [µ¼Ê¦ÍƼö]Î÷ÄϿƼ¼´óѧ¹ú·À/²ÄÁϵ¼Ê¦ÍƼö +3 ¼â½ÇСºÉ 2026-03-16 6/300 2026-03-16 23:21 by ¼â½ÇСºÉ
[¿¼ÑÐ] 326Çóµ÷¼Á +4 ŵ±´¶û»¯Ñ§½±êéê 2026-03-15 7/350 2026-03-16 17:11 by ŵ±´¶û»¯Ñ§½±êéê
[¿¼ÑÐ] ÖпÆÔº²ÄÁÏ273Çóµ÷¼Á +4 yzydy 2026-03-15 4/200 2026-03-16 15:59 by Gaodh_82
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖÐʦ·¶071000£¬325Çóµ÷¼Á +6 RuitingC 2026-03-12 6/300 2026-03-16 14:50 by ¿Éµ­²»¿ÉÍü
[¿¼ÑÐ] ÇóÀÏʦÊÕÁôµ÷¼Á +4 jiang½ª66 2026-03-14 5/250 2026-03-15 20:11 by Winj1e
[¿¼ÑÐ] 22408×Ü·Ö284Çóµ÷¼Á +3 InAspic 2026-03-13 3/150 2026-03-15 11:10 by zhq0425
[¿¼ÑÐ] 070305Çóµ÷¼Á +3 mlpqaz03 2026-03-14 4/200 2026-03-15 11:04 by peike
[¿¼ÑÐ] 294Çóµ÷¼Á +3 Zys010410@ 2026-03-13 4/200 2026-03-15 10:59 by zhq0425
[¿¼ÑÐ] ѧ˶285Çóµ÷¼Á +13 Wisjxn 2026-03-12 46/2300 2026-03-14 10:33 by JourneyLucky
[¿¼ÑÐ] 266Çóµ÷¼Á +4 ѧԱ97LZgn 2026-03-13 4/200 2026-03-14 08:37 by zhukairuo
[¿¼ÑÐ] 274Çóµ÷¼Á +3 S.H1 2026-03-12 3/150 2026-03-13 15:15 by JourneyLucky
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û